Abstract

Legend Biotech will report first-quarter 2026 results on May 12, 2026 Pre-Market; this preview compiles recent financial trends, current-quarter forecasts, and institutional commentary to frame expectations for revenue, margins, net income, and adjusted EPS.

Market Forecast

For the current quarter, the market’s baseline points to revenue of 307.04 million US dollars, adjusted EPS of -0.02, and EBIT of -3.24 million US dollars, with year-over-year growth implied at 58.58% for revenue and 90.53% for EPS. Forecast commentary implies a gross profit trajectory similar to recent quarters, with gross profit margin directionally stable and net losses narrowing; year-over-year revenue growth of 58.58% is expected as collaboration revenue continues to be recognized, while the net margin is expected to improve from the prior year. The company’s main business continues to be licensing and collaboration revenue recognition from partnered therapies, while the most promising growth driver remains milestone and revenue ramp tied to partnered cell therapy programs, expected to deliver 307.04 million US dollars this quarter, up 58.58% year over year.

Last Quarter Review

In the prior quarter, Legend Biotech posted revenue of 306.30 million US dollars, a gross profit margin of 26.63%, a GAAP net loss attributable to the parent company of 30.82 million US dollars, a net profit margin of -10.06%, and adjusted EPS of -0.16 with year-over-year growth at -206.67%. Collaboration and licensing revenue was the dominant contributor, comprising approximately 1.03 billion US dollars annualized with 1.03 billion US dollars attributed to “licensing and collaboration” and 0.30 million US dollars to “other,” reflecting the company’s primary revenue model.

A key highlight was robust top-line momentum, with revenue up 64.22% year over year as collaboration recognition accelerated. The main business highlight was licensing and collaboration revenue benefiting from milestone and amortization schedules under existing partnerships, which underpinned the company’s 306.30 million US dollars quarterly revenue and strong year-over-year expansion.

Current Quarter Outlook

Main business trajectory

Legend Biotech’s principal revenue stream is licensing and collaboration, which is expected to anchor performance again this quarter. With a forecast revenue of 307.04 million US dollars, the cadence is steady quarter over quarter and nearly 58.58% higher year over year, suggesting ongoing milestone recognition and amortization from previously signed agreements are in play. Margin characteristics for this revenue type produced a 26.63% gross profit margin last quarter; near-term gross margin is expected to remain broadly consistent as revenue mix is unlikely to shift materially within a single quarter. Net margin should improve sequentially as operating scale and controlled R&D and SG&A growth moderate losses, though management has historically prioritized pipeline investment that can pressure near-term profitability.

Most promising business driver

The most promising growth vector is the continued commercialization ramp and milestone timetable tied to partnered cell therapy programs, which support the forecast of 307.04 million US dollars in revenue, up 58.58% year over year. As these programs progress through commercial and late-development stages, the revenue mix can benefit from milestone receipts and higher contribution from product and profit-share streams over time. This trajectory should gradually lift gross margin beyond the 26.63% level, particularly as manufacturing and supply efficiencies are realized and collaboration economics shift from early recognition to sustained revenue streams. The durability of this driver depends on continued uptake in partnered markets, regulatory maintenance, and execution against capacity plans.

Stock-price swing factors this quarter

Share performance this quarter will likely hinge on three factors: revenue recognition cadence, margin progression, and expense discipline. Any deviation from the 307.04 million US dollars revenue forecast—either from the timing of milestone revenue or product-related contributions—could cause noticeable moves in the stock. Investors will monitor whether gross margin holds near the 26–27% band; a stronger print would signal improving manufacturing mix or higher-quality revenue composition, while a softer print could imply transitory cost absorption. On operating expenses, the run-rate implied by the prior quarter’s adjusted EPS of -0.16 and EBIT of -19.70 million US dollars suggests that even modest reductions in spend could rapidly compress losses; conversely, heavier pipeline investment would extend the path to profitability but bolster long-term optionality.

Analyst Opinions

The prevailing institutional stance skews bullish, with the majority of recent opinions emphasizing sustained top-line growth and improving loss ratios as collaboration revenue continues to scale. Analysts point to a revenue forecast near 307.04 million US dollars and an adjusted EPS trajectory toward -0.02 for the quarter, highlighting a constructive view on operating leverage as scale improves. Several well-followed institutions underscore that a 58.58% year-over-year revenue expansion sets a favorable backdrop for 2026, while acknowledging that timing of milestone revenue may inject volatility across quarters.

Bullish commentary concentrates on three themes. First, revenue momentum appears resilient, supported by ongoing recognition under partnership frameworks and commercial progress, which underpin the 307.04 million US dollars revenue expectation. Second, the earnings path shows incremental improvement: the current-quarter EPS forecast of -0.02 compares with last quarter’s -0.16, suggesting narrowing losses even with continued R&D investment. Third, expectations for gross margin stability around the mid-20% range reduce downside risk on profitability metrics; any upside surprise on cost absorption or product mix would reinforce the case for accelerating operating leverage into the second half of the year.

On balance, the bullish majority emphasizes that successful execution against collaboration milestones and steady commercialization progress should allow the company to meet or exceed its revenue forecast and deliver better-than-expected loss containment. The near-term debate is centered on the timing of milestone revenue, but supportive demand trends and maturing program economics lend confidence that the quarter can track to expectations while keeping the 2026 trajectory intact.